NowoTrade

SHPH

SHPH Shuttle Pharmaceuticals Holdings, Inc.

Stock · NasdaqCM · United States · Healthcare · US8256935003

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Shuttle Pharmaceuticals Holdings, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 5.59 USD +10.81%
52-week range 2.58 – 44.40
Dividend yield—
Market cap26.6M
NowoTrade score 2 Grade C

Price history

Daily prices in USD.

Updated 08 Nov 2026 14:52. Information, not advice.

Results

Next results —No date announced yet
Last results —Nothing reported yet
Beat the estimate — 
Average surprise — reported against the estimate, last 0 quarters

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2025 0 — -11.7M — -71.60 +91.3% -12.5M
2024 0 — -9.1M — -826.00 +6.4% -7.3M
2023 0 — -6.6M — -882.50 +30.0% -5.6M
2022 0 — -5M — -1,260.00 — -2.7M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by week
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
02 Dec 2024 – 06 Dec 2024 212.50 215.25 180.25 187.00 -11.79% 1,755
25 Nov 2024 – 29 Nov 2024 217.50 229.50 200.75 212.00 -2.64% 1,284
18 Nov 2024 – 22 Nov 2024 246.25 252.50 208.50 217.75 -12.64% 1,453
11 Nov 2024 – 15 Nov 2024 305.00 308.25 243.75 249.25 -14.05% 1,947
04 Nov 2024 – 08 Nov 2024 415.00 435.00 287.50 290.00 -30.54% 3,094
28 Oct 2024 – 01 Nov 2024 315.00 562.50 312.50 417.50 +33.60% 262,192
21 Oct 2024 – 25 Oct 2024 312.50 375.00 305.00 312.50 +5.04% 1,237
14 Oct 2024 – 18 Oct 2024 280.00 315.00 277.50 297.50 +6.25% 736
07 Oct 2024 – 11 Oct 2024 297.50 320.00 257.50 280.00 -3.86% 888
30 Sep 2024 – 04 Oct 2024 330.00 342.50 282.50 291.25 -11.74% 715
23 Sep 2024 – 27 Sep 2024 375.00 375.00 322.50 330.00 -9.59% 651
16 Sep 2024 – 20 Sep 2024 390.00 460.00 362.50 365.00 -14.12% 1,963
09 Sep 2024 – 13 Sep 2024 402.50 427.50 337.50 425.00 +4.29% 4,118
03 Sep 2024 – 06 Sep 2024 457.50 825.00 320.00 407.50 -15.54% 121,368
26 Aug 2024 – 30 Aug 2024 562.50 627.50 452.50 482.50 -16.45% 651
19 Aug 2024 – 23 Aug 2024 515.00 595.00 467.25 577.50 +10.53% 575
12 Aug 2024 – 16 Aug 2024 640.00 646.00 460.00 522.50 -21.78% 1,921
05 Aug 2024 – 09 Aug 2024 700.00 780.00 634.00 668.00 -9.73% 544
29 Jul 2024 – 02 Aug 2024 860.00 898.00 700.00 740.00 -15.91% 253
22 Jul 2024 – 26 Jul 2024 862.00 1,040.00 830.00 880.00 -4.35% 836
15 Jul 2024 – 19 Jul 2024 848.00 1,074.00 800.00 920.00 +8.49% 6,005
08 Jul 2024 – 12 Jul 2024 800.00 910.00 720.00 848.00 +9.00% 414
01 Jul 2024 – 05 Jul 2024 780.00 810.00 742.00 778.00 -2.75% 67
24 Jun 2024 – 28 Jun 2024 760.00 820.00 720.00 800.00 +7.24% 135
17 Jun 2024 – 21 Jun 2024 840.00 840.00 746.00 746.00 -13.66% 80

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

Key data

Previous close
5.04 USD
Market cap
26.6M
Exchange
NasdaqCM
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 8.8 / 25 No figures for this part: it counts as a cautious 35%. —
Quality Return on equity, net margin and how stable the margins are. 0.0 / 25
  • ROE of -90%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 0.0 / 20
  • Free cash flow yield of -10.7%
Valuation Free cash flow yield and the P/E against its sector. 0.0 / 15 —
Analysts How far the analysts' average target is from today's price. 3.5 / 10 No figures for this part: it counts as a cautious 35%. —
  • Score capped at 60: free cash flow was negative in two of the last three years
  • Thin interest cover: operating profit is only -168.3× the interest
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 60% of the figures (grade C). Warnings take 12 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
FigureValueReading Sector median
Price / book 0.29× Good 3.8×
EV / EBITDA -2.76× Weak 12.61×
Free cash flow yield -10.7% Weak 2.5%
Quality
FigureValueReading Sector median
Gross margin 0% Weak 58.6%
Operating margin 0% Weak 7.6%
Net margin 0% Weak 2.7%
Return on equity -90.1% Weak 5.7%
Return on assets -49.5% Weak 3.5%
Financial health
FigureValueReading Sector median
Debt / equity 0.01× Good 0.48×
Interest cover -168.25× Weak 2.65×
Current ratio 0.11× Weak 2.36×

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow SHPH and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in